Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

BCRX - BioCryst Pharmaceuticals, Inc.... | Finranks

Home

/

BCRX

B

BioCryst Pharmaceuticals, Inc. (BCRX)

NMS – Цена в реальном времени. Валюта: USD

10.56

+0.23 (2.18%)

Рынок открыт: Aug 12, 2026, 3:10 PM EDT

10.23

-0.11 (-1.06%)

Предыдущая сессия: Aug 11, 2026, 7:34 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Wall Street Analysts See a 98.74% Upside in BioCryst (BCRX): Can the Stock Really Move This High?

Wall Street Analysts See a 98.74% Upside in BioCryst (BCRX): Can the Stock Really Move This High?

The consensus price target hints at a 98.7% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Implied Volatility Surging for BioCryst Pharmaceuticals Stock Options

Implied Volatility Surging for BioCryst Pharmaceuticals Stock Options

Investors need to pay close attention to BCRX stock based on the movements in the options market lately.

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?

BioCryst Pharmaceuticals (NASDAQ:BCRX) closed at $9.84 on August 10, 2026, giving the Durham-based rare-disease specialist a market cap of roughly $2.5 billion.

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2026 Earnings Call Transcript

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2026 Earnings Call Transcript

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2026 Earnings Call Transcript

BioCryst Pharmaceuticals Q2 Earnings Call Highlights

BioCryst Pharmaceuticals Q2 Earnings Call Highlights

BioCryst Pharmaceuticals NASDAQ: BCRX reported second-quarter results marked by growth in ORLADEYO revenue, the start of shipments for its pediatric oral-pellet formulation, and completion of enrollment in its pivotal navenibart trial for hereditary angioedema, or HAE.

BioCryst Pharmaceuticals (BCRX) Tops Q2 Earnings and Revenue Estimates

BioCryst Pharmaceuticals (BCRX) Tops Q2 Earnings and Revenue Estimates

BioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $0.3 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.15 per share a year ago.

BioCryst Reports Second Quarter 2026 Financial Results

BioCryst Reports Second Quarter 2026 Financial Results

— Total net revenue of $218.3 million and ORLADEYO ® net revenue of $158.2 million — — Operating profit of $98.5 million and Non-GAAP operating profit of $113.2 million — — Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $690 million to $715 million — — Began shipping ORLADEYO oral pellets to pediatric patients on August 3 — — Completed enrollment in ALPHA-ORBIT, the ongoing pivotal study of navenibart — RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the quarter ended June 30, 2026, and provided a business update.

Видео

No Data

There is no data to display

Пресс-релизы

BioCryst Reports Second Quarter 2026 Financial Results

BioCryst Reports Second Quarter 2026 Financial Results

— Total net revenue of $218.3 million and ORLADEYO ® net revenue of $158.2 million — — Operating profit of $98.5 million and Non-GAAP operating profit of $113.2 million — — Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $690 million to $715 million — — Began shipping ORLADEYO oral pellets to pediatric patients on August 3 — — Completed enrollment in ALPHA-ORBIT, the ongoing pivotal study of navenibart — RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the quarter ended June 30, 2026, and provided a business update.